Dietz J - Search Results

1

Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals.

Howe AYM, Rodrigo C, Cunningham EB, Douglas MW, Dietz J, Grebely J, Popping S, Sfalcin JA, Parczewski M, Sarrazin C, de Salazar A, Fuentes A, Sayan M, Quer J, Kjellin M, Kileng H, Mor O, Lennerstrand J, Fourati S, Di Maio VC, Chulanov V, Pawlotsky JM, Harrigan PR, Ceccherini-Silberstein F, Garcia F; SHARED Collaborators. Howe AYM, et al. Among authors: dietz j. JHEP Rep. 2022 Feb 24;4(5):100462. doi: 10.1016/j.jhepr.2022.100462. eCollection 2022 May. JHEP Rep. 2022. PMID: 35434589 Free PMC article.

2

Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients.

Dietz J, Schelhorn SE, Fitting D, Mihm U, Susser S, Welker MW, Füller C, Däumer M, Teuber G, Wedemeyer H, Berg T, Lengauer T, Zeuzem S, Herrmann E, Sarrazin C. Dietz J, et al. J Virol. 2013 Jun;87(11):6172-81. doi: 10.1128/JVI.02778-12. Epub 2013 Mar 27. J Virol. 2013. PMID: 23536652 Free PMC article. Clinical Trial.

3

A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C.

Owusu Sekyere S, Suneetha PV, Kraft AR, Zhang S, Dietz J, Sarrazin C, Manns MP, Schlaphoff V, Cornberg M, Wedemeyer H. Owusu Sekyere S, et al. Among authors: dietz j. J Hepatol. 2015 Jan;62(1):31-40. doi: 10.1016/j.jhep.2014.08.008. Epub 2014 Aug 15. J Hepatol. 2015. PMID: 25131771

4

Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients.

Dietz J, Susser S, Berkowski C, Perner D, Zeuzem S, Sarrazin C. Dietz J, et al. PLoS One. 2015 Aug 28;10(8):e0134395. doi: 10.1371/journal.pone.0134395. eCollection 2015. PLoS One. 2015. PMID: 26317755 Free PMC article.

5

Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3.

Peiffer KH, Sommer L, Susser S, Vermehren J, Herrmann E, Döring M, Dietz J, Perner D, Berkowski C, Zeuzem S, Sarrazin C. Peiffer KH, et al. Among authors: dietz j. Hepatology. 2016 Jan;63(1):63-73. doi: 10.1002/hep.28255. Epub 2015 Nov 25. Hepatology. 2016. PMID: 26406534

6

Hepatitis C "true" late relapse beyond 48weeks of sustained virologic response after direct acting antiviral therapy.

Klag T, Dietz J, Werner CR, Schwarz JM, Lauer UM, Beck R, Malek NP, Sarrazin C, Berg CP. Klag T, et al. Among authors: dietz j. J Hepatol. 2017 Apr;66(4):862-863. doi: 10.1016/j.jhep.2017.01.002. Epub 2017 Jan 9. J Hepatol. 2017. PMID: 28082147 No abstract available.

7

Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras.

Susser S, Dietz J, Schlevogt B, Zuckerman E, Barak M, Piazzolla V, Howe A, Hinrichsen H, Passmann S, Daniel R, Cornberg M, Mangia A, Zeuzem S, Sarrazin C. Susser S, et al. Among authors: dietz j. J Hepatol. 2017 Oct;67(4):680-686. doi: 10.1016/j.jhep.2017.05.027. Epub 2017 Jun 13. J Hepatol. 2017. PMID: 28619439

8

Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.

Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Müllhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Hüppe D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, von Hahn T, Berg T, Zeuzem S, Sarrazin C; European HCV Resistance Study Group. Dietz J, et al. Gastroenterology. 2018 Mar;154(4):976-988.e4. doi: 10.1053/j.gastro.2017.11.007. Epub 2017 Nov 13. Gastroenterology. 2018. PMID: 29146520

9

Interferon-free treatment choice according to baseline RASs leads to high SVR rates in HCV genotype 1 infected patients.

Peiffer KH, Vermehren J, Kuhnhenn L, Susser S, Dietz J, Finkelmeier F, Weiler N, Welzel T, Grammatikos G, Zeuzem S, Sarrazin C. Peiffer KH, et al. Among authors: dietz j. J Infect Chemother. 2018 Jul;24(7):524-530. doi: 10.1016/j.jiac.2018.02.008. Epub 2018 Apr 5. J Infect Chemother. 2018. PMID: 29628383

10

Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients.

Mölleken C, Ahrens M, Schlosser A, Dietz J, Eisenacher M, Meyer HE, Schmiegel W, Holmskov U, Sarrazin C, Sorensen GL, Sitek B, Bracht T. Mölleken C, et al. Among authors: dietz j. Clin Mol Hepatol. 2019 Mar;25(1):42-51. doi: 10.3350/cmh.2018.0029. Epub 2018 Nov 19. Clin Mol Hepatol. 2019. PMID: 30449076 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

461 results

Search Page